Literature DB >> 2299255

Release of tumor necrosis factor by alveolar macrophages of patients with sarcoidosis.

R P Baughman1, S A Strohofer, J Buchsbaum, E E Lower.   

Abstract

Tumor necrosis factor (TNF) is a monokine released by macrophages and is important in the inflammatory response. We compared the spontaneous release of TNF by alveolar macrophages (AMs) from patients with symptomatic pulmonary sarcoidosis, some of whom were receiving corticosteroid therapy, with AMs from control smokers. TNF was released from AMs of sarcoidosis patients at significantly higher levels than was released by control AM subjects (sarcoids, 15 U/ml [0 to 1140 U (median [range]]); controls, all less than 5 U/ml, p less than 0.01). By using a specific polyclonal antibody, the detected TNF was found to be TNF-alpha. Among the sarcoidosis patients, the amount of TNF released was significantly lower for those patients given treatment with corticosteroids (5 U/ml [0 to 15 U/ml]) compared with untreated persons (50 U/ml [0 to 1140 U/ml], p less than 0.05). In vitro studies demonstrated that incubation of peripheral blood monocytes or AMs with dexamethasone for 42 hours suppressed subsequent release of TNF. We conclude that AMs from sarcoidosis patients often spontaneously release TNF and this release is suppressed by prolonged corticosteroid therapy.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2299255

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  40 in total

Review 1.  A clinical approach to the use of methotrexate for sarcoidosis.

Authors:  R P Baughman; E E Lower
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

2.  Osseous sarcoidosis: a case series.

Authors:  Halyna Kuzyshyn; David Feinstein; Sharon L Kolasinski; Hala Eid
Journal:  Rheumatol Int       Date:  2014-11-02       Impact factor: 2.631

Review 3.  A concise review of pulmonary sarcoidosis.

Authors:  Robert P Baughman; Daniel A Culver; Marc A Judson
Journal:  Am J Respir Crit Care Med       Date:  2010-10-29       Impact factor: 21.405

Review 4.  Neurosarcoidosis.

Authors:  Dakshinamurty Gullapalli; Lawrence H Phillips
Journal:  Curr Neurol Neurosci Rep       Date:  2004-11       Impact factor: 5.081

5.  Shed soluble ICAM-1 molecules in bronchoalveolar lavage cell supernatants and serum of patients with pulmonary sarcoidosis.

Authors:  I Bäumer; G Zissel; M Schlaak; J Müller-Quernheim
Journal:  Lung       Date:  1997       Impact factor: 2.584

6.  Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis.

Authors:  Nadera J Sweiss; Imre Noth; Mehdi Mirsaeidi; Wei Zhang; Edward T Naureckas; D Kyle Hogarth; Mary Strek; Philip Caligiuri; Roberto F Machado; Timothy B Niewold; Joe G N Garcia; Aileen L Pangan; Robert P Baughman
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2014-04-18       Impact factor: 0.670

7.  Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil.

Authors:  Michael Moravan; Benjamin M Segal
Journal:  Neurology       Date:  2009-01-27       Impact factor: 9.910

8.  [Intracerebral lesions after TNF-alpha inhibitor therapy with pre-existing sarcoidosis and sacroiliitis].

Authors:  H Merwald-Fraenk; B Piper; H Mörtlbauer; M Welcker; I I Vallbracht-Ackermann
Journal:  Z Rheumatol       Date:  2012-12       Impact factor: 1.372

9.  Correlation of GM-CSF mRNA in bronchoalveolar fluid with indices of clinical activity in sarcoidosis.

Authors:  A Itoh; E Yamaguchi; K Furuya; N Hizawa; N Ohnuma; Y Kawakami; N Kuzumaki
Journal:  Thorax       Date:  1993-12       Impact factor: 9.139

10.  Dramatic response to infliximab in refractory neurosarcoidosis.

Authors:  Sreekanth Chintamaneni; Aarat M Patel; Samuel B Pegram; Hirenkumar Patel; Heidi Roppelt
Journal:  Ann Indian Acad Neurol       Date:  2010-07       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.